Literature DB >> 2433331

Cationization of protein antigens. I. Alteration of immunogenic properties.

A Muckerheide, R J Apple, A J Pesce, J G Michael.   

Abstract

We have shown that a cationized form of bovine serum albumin (BSA) produced by substituting anionic side chain carboxylic groups with aminoethylamide groups possesses unique immunologic properties. The two forms of antigen, native (nBSA) and cationized (cBSA), cross-react at the level of the B cell, as evidenced by the ability of antibody raised against one form to react with the other and by inhibition assays using ELISA. T cell cross-reactivity was also observed in proliferation assays, but the amount of cBSA required for stimulation was 500 times less than the amount of native protein needed. In vivo, cBSA produced responses which, at their optimal levels, were at least double the response to nBSA and which showed a different kinetic pattern, peaking later and lasting longer than the response to the native molecule. Moreover, antibodies were produced in response to administration of cBSA but not nBSA when given i.v. in saline, without an adjuvant. Although a mechanism for these phenomena is not yet clear, we speculate that the cBSA may have a greater affinity for antigen-presenting cells or for the T cell receptor, or that the altered structure may enhance recognition of the molecule by APC and/or helper T cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433331

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Anti-miroestrol polyclonal antibodies: a comparison of immunogen preparations used to obtain desired antibody properties.

Authors:  Tharita Kitisripanya; Kamonthip Jutathis; Chadathorn Inyai; Jukrapun Komaikul; Orapin Udomsin; Gorawit Yusakul; Hiroyuki Tanaka; Waraporn Putalun
Journal:  J Nat Med       Date:  2015-11-13       Impact factor: 2.343

Review 2.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

3.  Activation of a murine T-cell hybridoma by cationized bacteria.

Authors:  D N Shapiro; J Varani; I Ginsburg
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

4.  Active in situ immune complex glomerulonephritis using the hapten-carrier system: role of epitope density in cationic antigens.

Authors:  S Kagami; M Miyao; F Shimizu; T Oite
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

5.  Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens.

Authors:  Nijaporn Yanasarn; Brian R Sloat; Zhengrong Cui
Journal:  Mol Pharm       Date:  2011-06-07       Impact factor: 4.939

6.  Antigenic charge as a factor in resistance to immunosuppressive therapy.

Authors:  S G Adler; H Y Wang; A H Cohen; W A Border
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

7.  Siderophore vaccine conjugates protect against uropathogenic Escherichia coli urinary tract infection.

Authors:  Laura A Mike; Sara N Smith; Christopher A Sumner; Kathryn A Eaton; Harry L T Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

8.  Glomerular lesions induced in the rabbit by physicochemically altered homologous IgG.

Authors:  F Cavalot; M Miyata; A Vladutiu; V Terranova; S Dubiski; R Burlingame; E Tan; J Brentjens; F Milgrom; G Andres
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

9.  Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H).

Authors:  A E Gharavi; L R Sammaritano; J Wen; K B Elkon
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Molecular factors in dendritic cell responses to adsorbed glycoconjugates.

Authors:  Nathan A Hotaling; Richard D Cummings; Daniel M Ratner; Julia E Babensee
Journal:  Biomaterials       Date:  2014-04-16       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.